Aurisco Pharmaceutical Co. Ltd.SSE: 605116

Announcement on Obtaining Drug Registration Approval by the Wholly-owned Subsidiary

· Issued by Aurisco Pharmaceutical Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · · 2 pages · Chinese

Summary by 6ix AI

Aurisco Pharmaceutical Co. Ltd. announced that its wholly-owned subsidiary has received drug registration approval for a new product. The approved product is a combination of estradiol and dydrogesterone tablets, intended for treating menopausal symptoms. This approval is expected to enhance the company's market competitiveness and positively impact its financial performance. The company emphasizes the importance of quality control in drug development and manufacturing processes.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Release

Announcement on Obtaining Drug Registration Approval by the Wholly-owned Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Aurisco Pharmaceutical Co. Ltd. on 6ix

Earlier from Aurisco Pharmaceutical

Later from Aurisco Pharmaceutical

All Aurisco Pharmaceutical news releases